Alaunos Therapeutics (NASDAQ:TCRT) Trading 8.9% Higher – Still a Buy?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares traded up 8.9% during mid-day trading on Thursday . The stock traded as high as $3.09 and last traded at $3.06. 33,033 shares changed hands during mid-day trading, an increase of 152% from the average session volume of 13,127 shares. The stock had previously closed at $2.81.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Alaunos Therapeutics Stock Performance

The firm has a market capitalization of $74.73 million, a P/E ratio of -1.44 and a beta of -1.13. The firm has a 50-day moving average of $2.78 and a 200-day moving average of $3.05.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.59) earnings per share for the quarter.

Institutional Investors Weigh In On Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics as of its most recent filing with the SEC. 27.72% of the stock is currently owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.